NBIX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $74,251,850.99

Neurocrine Biosciences Insider Trading History Chart

Neurocrine Biosciences Share Price & Price History

^$135.42

▲ +0.46 (0.34%)

As of 12/20/2024 06:31 PM ET

Days: 30 | 90 | 365

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

Neurocrine Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2024	Ingrid Delaet	Insider	Sell	1,091	$135.00	$147,285.00	2,507
11/29/2024	Jude Onyia	Insider	Sell	2,331	$126.29	$294,381.99	15,449
8/15/2024	William H. Rastetter	Director	Sell	14,250	$146.69	$2,090,332.50	37,491
8/13/2024	Gary A. Lyons	Director	Sell	11,570	$150.43	$1,740,475.10	119,047
8/13/2024	Ingrid Delaet	Insider	Sell	7,143	$150.10	$1,072,164.30	2,507
8/13/2024	Matt Abernethy	CFO	Sell	14,100	$150.38	$2,120,358.00	31,528
8/6/2024	Ingrid Delaet	Insider	Sell	273	$147.70	$40,322.10	6,607
8/1/2024	Julie Cooke	Insider	Sell	12,632	$153.26	$1,935,980.32	18,202
7/16/2024	Gary A. Lyons	Director	Sell	930	$150.03	$139,527.90	119,047
7/16/2024	Julie Cooke	Insider	Sell	900	$150.04	$135,036.00	18,202
7/1/2024	Julie Cooke	Insider	Sell	10,000	$140.19	$1,401,900.00	18,202
5/29/2024	Stephen A. Sherwin	Director	Sell	40,000	$133.46	$5,338,400.00	26,504
5/17/2024	Shalini Sharp	Director	Sell	1,106	$141.90	$156,941.40	994
5/15/2024	Matt Abernethy	CFO	Sell	15,000	$140.24	$2,103,600.00	31,528
5/14/2024	Gary A. Lyons	Director	Sell	12,500	$135.63	$1,695,375.00	116,947
5/6/2024	Ingrid Delaet	Insider	Sell	273	$140.55	$38,370.15	7,507
4/15/2024	Eric Benevich	Insider	Sell	19,818	$133.36	$2,642,928.48	40,778
3/21/2024	Ingrid Delaet	Insider	Sell	5,000	$145.06	$725,300.00	7,507
3/14/2024	Eric Benevich	Insider	Sell	75,000	$139.38	$10,453,500.00	40,778
3/14/2024	George J. Morrow	Director	Sell	40,000	$139.42	$5,576,800.00
3/11/2024	Ingrid Delaet	Insider	Sell	200	$140.00	$28,000.00	7,507
3/11/2024	Richard F. Pops	Director	Sell	100	$140.00	$14,000.00	29,512
3/8/2024	Ingrid Delaet	Insider	Sell	1,800	$140.03	$252,054.00	7,507
3/8/2024	Richard F. Pops	Director	Sell	1,700	$140.05	$238,085.00	29,512
2/29/2024	Ingrid Delaet	Insider	Sell	273	$135.51	$36,994.23	7,507
2/27/2024	Leslie V. Norwalk	Director	Sell	8,000	$135.67	$1,085,360.00
2/20/2024	Richard F. Pops	Director	Sell	15,000	$132.47	$1,987,050.00	29,512
2/13/2024	Eiry Roberts	Insider	Sell	1,114	$132.96	$148,117.44	23,716
2/13/2024	Kevin Charles Gorman	CEO	Sell	2,832	$133.02	$376,712.64	514,596
2/13/2024	Matt Abernethy	CFO	Sell	1,352	$132.85	$179,613.20	31,528
2/8/2024	David W. Boyer	Insider	Sell	1,328	$135.41	$179,824.48	4,895
2/8/2024	Kevin Charles Gorman	CEO	Sell	2,274	$134.15	$305,057.10	506,962
2/8/2024	Matt Abernethy	CFO	Sell	980	$134.21	$131,525.80	30,314
2/6/2024	David W. Boyer	Insider	Sell	456	$141.96	$64,733.76	4,894
2/6/2024	Kevin Charles Gorman	CEO	Sell	3,040	$142.18	$432,227.20	504,919
2/6/2024	Matt Abernethy	CFO	Sell	1,280	$142.19	$182,003.20	29,434
1/31/2024	Eiry Roberts	Insider	Sell	1,457	$140.79	$205,131.03	20,832
1/31/2024	Kevin Charles Gorman	CEO	Sell	2,707	$140.69	$380,847.83	502,188
1/31/2024	Matt Abernethy	CFO	Sell	1,283	$140.72	$180,543.76	28,284
1/22/2024	Darin Lippoldt	Insider	Sell	10,000	$139.86	$1,398,600.00	35,882
1/8/2024	Kevin Charles Gorman	CEO	Sell	105,835	$132.44	$14,016,787.40	499,754
1/2/2024	Kyle Gano	Insider	Sell	75,000	$131.47	$9,860,250.00	130,250
1/2/2024	William H. Rastetter	Director	Sell	11,044	$131.47	$1,451,954.68	51,741
12/22/2023	Eiry Roberts	Insider	Sell	10,000	$126.74	$1,267,400.00	19,521
12/12/2023	Eiry Roberts	Insider	Sell	13,925	$120.30	$1,675,177.50	29,521
12/8/2023	Eiry Roberts	Insider	Sell	300	$120.10	$36,030.00	29,521
12/6/2023	Darin Lippoldt	Insider	Sell	20,830	$119.86	$2,496,683.80	35,882
12/1/2023	Gary A. Lyons	Director	Sell	5,000	$116.77	$583,850.00	203,697
11/29/2023	Jude Onyia	Insider	Sell	2,331	$113.57	$264,731.67	11,732
11/27/2023	Darin Lippoldt	Insider	Sell	10,919	$112.27	$1,225,876.13	35,882
10/2/2023	David W. Boyer	Insider	Sell	1,437	$112.68	$161,921.16	4,894
9/12/2023	Gary A. Lyons	Director	Sell	5,000	$115.02	$575,100.00	203,697
9/1/2023	Gary A. Lyons	Director	Sell	5,000	$110.06	$550,300.00	203,697
9/1/2023	Julie Cooke	Insider	Sell	824	$110.93	$91,406.32	17,263
8/30/2023	David W. Boyer	Insider	Sell	2,733	$107.60	$294,070.80	3,460
8/28/2023	Ingrid Delaet	Insider	Sell	1,431	$107.52	$153,861.12	5,931
8/21/2023	Jude Onyia	Insider	Sell	3,198	$107.37	$343,369.26	9,638
8/21/2023	Kevin Charles Gorman	CEO	Sell	9,328	$107.40	$1,001,827.20	499,754
8/21/2023	Matt Abernethy	CFO	Sell	2,132	$107.39	$228,955.48	27,131
5/1/2023	Julie Cooke	Insider	Sell	11,397	$103.89	$1,184,034.33	16,169
5/1/2023	William H. Rastetter	Director	Sell	4,300	$101.43	$436,149.00	42,785
4/24/2023	Eiry Roberts	Insider	Sell	14,400	$103.48	$1,490,112.00	26,644
4/21/2023	William H. Rastetter	Director	Sell	6,034	$105.04	$633,811.36	39,460
4/19/2023	William H. Rastetter	Director	Sell	903	$105.00	$94,815.00	34,729
2/23/2023	Neurocrine Biosciences Inc	Major Shareholder	Buy	4,395,588	$8.88	$39,032,821.44	8,575,316
2/8/2023	Eric Benevich	Insider	Sell	980	$104.12	$102,037.60	34,381
2/8/2023	Kevin Charles Gorman	CEO	Sell	2,274	$104.30	$237,178.20	491,365
2/7/2023	Matt Abernethy	CFO	Sell	26,328	$102.40	$2,695,987.20	24,333
2/6/2023	Eric Benevich	Insider	Sell	1,280	$105.63	$135,206.40	17,879
2/6/2023	Kevin Charles Gorman	CEO	Sell	3,040	$105.68	$321,267.20	468,008
1/31/2023	Eiry Roberts	Insider	Sell	1,457	$109.99	$160,255.43	26,171
1/31/2023	Kevin Charles Gorman	CEO	Sell	2,707	$110.08	$297,986.56	465,278
1/31/2023	Matt Abernethy	CFO	Sell	1,283	$109.98	$141,104.34	21,357
1/6/2023	Eric Benevich	Insider	Sell	400	$125.00	$50,000.00	15,643
1/3/2023	Stephen A. Sherwin	Director	Sell	30,000	$118.86	$3,565,800.00	25,055
11/30/2022	Eric Benevich	Insider	Sell	50,000	$125.90	$6,295,000.00	15,643
11/10/2022	Eric Benevich	Insider	Sell	100	$125.36	$12,536.00	15,643
11/8/2022	Eric Benevich	Insider	Sell	24,593	$125.33	$3,082,240.69	15,643
11/3/2022	Darin Lippoldt	Insider	Sell	4,518	$125.02	$564,840.36	29,234
11/1/2022	Darin Lippoldt	Insider	Sell	10,000	$120.09	$1,200,900.00	29,234
10/31/2022	Gary A. Lyons	Director	Sell	15,000	$114.76	$1,721,400.00	203,697
10/27/2022	Darin Lippoldt	Insider	Sell	4,923	$115.04	$566,341.92	29,234
10/17/2022	Eric Benevich	Insider	Sell	4,960	$110.82	$549,667.20	15,643
10/4/2022	Gary A. Lyons	Director	Sell	5,000	$110.54	$552,700.00	203,697
10/3/2022	David W. Boyer	Insider	Sell	1,437	$106.59	$153,169.83	4,214
8/12/2022	Malcolm Lloyd-Smith	Insider	Sell	21,533	$105.95	$2,281,421.35	18,888
6/27/2022	Julie Cooke	Insider	Sell	754	$100.00	$75,400.00	16,918
5/9/2022	Richard F. Pops	Director	Sell	15,000	$76.30	$1,144,500.00	29,512
4/25/2022	Gary A. Lyons	Director	Sell	15,000	$92.76	$1,391,400.00	208,697
4/1/2022	William H. Rastetter	Director	Sell	10,728	$94.93	$1,018,409.04	34,022
3/22/2022	Darin Lippoldt	Insider	Sell	8,455	$95.05	$803,647.75
3/18/2022	Darin Lippoldt	Insider	Sell	300	$95.00	$28,500.00
2/7/2022	David W. Boyer	Insider	Sell	240	$81.07	$19,456.80
2/7/2022	Kevin Charles Gorman	CEO	Sell	8,710	$80.82	$703,942.20
2/7/2022	Matt Abernethy	CFO	Sell	3,310	$80.79	$267,414.90
1/24/2022	Stephen A. Sherwin	Director	Sell	15,000	$74.43	$1,116,450.00
1/10/2022	Eiry Roberts	Insider	Sell	2,632	$74.50	$196,084.00
1/5/2022	Kyle Gano	Insider	Sell	28,266	$85.50	$2,416,743.00

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

SEC Filings (Institutional Ownership Changes) for Neurocrine Biosciences (NASDAQ:NBIX)

92.59% of Neurocrine Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Neurocrine Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/19/2024	Principal Financial Group Inc.	253,186	$29.17M	0.0%	-32.3%	0.250%
12/6/2024	Retirement Systems of Alabama	122,661	$14.13M	0.1%	-1.2%	0.121%
11/27/2024	Franklin Resources Inc.	664,336	$77.36M	0.0%	-17.8%	0.656%
11/26/2024	Tri Ri Asset Management Corp	28,088	$3.24M	1.7%	N/A	0.028%
11/25/2024	Tidal Investments LLC	15,043	$1.73M	0.0%	+52.8%	0.015%
11/25/2024	Wilmington Savings Fund Society FSB	3,333	$0.38M	0.0%	N/A	0.003%
11/25/2024	Sanctuary Advisors LLC	7,649	$0.96M	0.0%	+103.9%	0.008%
11/21/2024	Tri Ri Asset Management Corp	28,088	$3.11M	3.5%	N/A	0.028%
11/20/2024	Virtu Financial LLC	17,230	$1.99M	0.1%	N/A	0.017%
11/18/2024	Teachers Retirement System of The State of Kentucky	30,400	$3.50M	0.0%	-2.8%	0.030%
11/18/2024	Toronto Dominion Bank	12,684	$1.46M	0.0%	+32.8%	0.013%
11/18/2024	Coldstream Capital Management Inc.	3,917	$0.45M	0.0%	+15.2%	0.004%
11/16/2024	Geode Capital Management LLC	1,859,232	$213.77M	0.0%	+2.2%	1.836%
11/15/2024	Vestcor Inc	20,208	$2.33M	0.1%	-19.5%	0.020%
11/15/2024	M&T Bank Corp	5,656	$0.65M	0.0%	-5.7%	0.006%
11/15/2024	Barclays PLC	181,591	$20.92M	0.0%	-18.3%	0.179%
11/15/2024	Peloton Wealth Strategists	3,515	$0.41M	0.2%	N/A	0.003%
11/15/2024	Public Employees Retirement System of Ohio	42,944	$4.95M	0.0%	-12.3%	0.042%
11/15/2024	Nomura Asset Management Co. Ltd.	56,275	$6.48M	0.0%	-2.6%	0.056%
11/15/2024	Y Intercept Hong Kong Ltd	31,781	$3.66M	0.2%	N/A	0.031%
11/15/2024	MML Investors Services LLC	9,833	$1.13M	0.0%	-1.3%	0.010%
11/15/2024	Orion Portfolio Solutions LLC	26,934	$3.10M	0.1%	-0.8%	0.027%
11/15/2024	XTX Topco Ltd	8,665	$1M	0.1%	+159.2%	0.009%
11/15/2024	National Bank of Canada FI	1,351	$0.16M	0.0%	+83.3%	0.001%
11/15/2024	iA Global Asset Management Inc.	2,652	$0.31M	0.0%	N/A	0.003%
11/15/2024	EP Wealth Advisors LLC	4,191	$0.48M	0.0%	N/A	0.004%
11/15/2024	Wellington Management Group LLP	718,226	$82.75M	0.0%	-20.2%	0.709%
11/15/2024	Worldquant Millennium Advisors LLC	107,482	$12.38M	0.1%	-32.2%	0.106%
11/15/2024	Soros Fund Management LLC	150,000	$17.28M	0.2%	-23.0%	0.148%
11/15/2024	State Street Corp	5,148,293	$593.19M	0.0%	+11.7%	5.085%
11/15/2024	Stevens Capital Management LP	2,003	$0.23M	0.0%	N/A	0.002%
11/15/2024	Quantinno Capital Management LP	2,239	$0.26M	0.0%	+25.0%	0.002%
11/15/2024	Quarry LP	2,500	$0.29M	0.1%	+11,263.6%	0.002%
11/15/2024	Royal London Asset Management Ltd.	51,533	$5.94M	0.0%	+13.3%	0.051%
11/15/2024	Parkman Healthcare Partners LLC	129,840	$14.96M	1.9%	+12.7%	0.128%
11/15/2024	Integrated Wealth Concepts LLC	1,950	$0.23M	0.0%	-6.8%	0.002%
11/15/2024	Investment Management Corp of Ontario	4,778	$0.55M	0.0%	+33.5%	0.005%
11/15/2024	Jacobs Levy Equity Management Inc.	524,168	$60.40M	0.2%	-27.3%	0.518%
11/15/2024	Janus Henderson Group PLC	792,196	$91.28M	0.0%	-18.4%	0.782%
11/15/2024	HighTower Advisors LLC	9,587	$1.10M	0.0%	-67.4%	0.009%
11/15/2024	Centiva Capital LP	2,079	$0.24M	0.0%	-26.3%	0.002%
11/15/2024	Erste Asset Management GmbH	23,800	$2.74M	0.0%	N/A	0.024%
11/15/2024	True Wealth Design LLC	592	$68K	0.0%	+11,740.0%	0.001%
11/14/2024	Bellevue Group AG	1,863,800	$214.75M	3.5%	-1.8%	1.841%
11/14/2024	BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp	16,786	$1.93M	0.0%	-11.9%	0.017%
11/14/2024	Edgestream Partners L.P.	5,266	$0.61M	0.0%	-88.1%	0.005%
11/14/2024	Caisse DE Depot ET Placement DU Quebec	736,910	$84.91M	0.2%	+12.3%	0.728%
11/14/2024	PDT Partners LLC	14,900	$1.72M	0.2%	N/A	0.015%
11/14/2024	Braidwell LP	917,674	$105.73M	3.0%	+20.9%	0.906%
11/14/2024	Verition Fund Management LLC	8,325	$0.96M	0.0%	N/A	0.008%
11/14/2024	Martingale Asset Management L P	26,311	$3.03M	0.1%	-11.4%	0.026%
11/14/2024	Vinva Investment Management Ltd	38,540	$4.43M	0.2%	+130.2%	0.038%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	894,217	$103.03M	0.0%	-2.0%	0.883%
11/14/2024	Zurcher Kantonalbank Zurich Cantonalbank	60,900	$7.02M	0.0%	-32.3%	0.060%
11/14/2024	FORA Capital LLC	16,752	$1.93M	0.2%	N/A	0.017%
11/14/2024	MetLife Investment Management LLC	56,707	$6.53M	0.0%	-1.6%	0.056%
11/14/2024	CreativeOne Wealth LLC	8,408	$0.97M	0.0%	+190.5%	0.008%
11/14/2024	Blueshift Asset Management LLC	4,284	$0.49M	0.1%	N/A	0.004%
11/13/2024	Glenmede Trust Co. NA	10,261	$1.18M	0.0%	-7.5%	0.010%
11/13/2024	Bridgewater Associates LP	135,186	$15.58M	0.1%	+54.4%	0.134%
11/13/2024	BNP Paribas Financial Markets	533,324	$61.45M	0.0%	+23.9%	0.527%
11/13/2024	Quantbot Technologies LP	769	$89K	0.0%	N/A	0.001%
11/13/2024	FMR LLC	246,106	$28.36M	0.0%	-28.0%	0.243%
11/13/2024	Dai ichi Life Insurance Company Ltd	42,119	$4.85M	0.1%	-13.1%	0.042%
11/13/2024	The Manufacturers Life Insurance Company	117,252	$13.51M	0.0%	-6.5%	0.116%
11/13/2024	Qsemble Capital Management LP	10,743	$1.24M	0.2%	N/A	0.011%
11/13/2024	Bank of Montreal Can	55,244	$6.36M	0.0%	+40.4%	0.055%
11/13/2024	Truvestments Capital LLC	544	$63K	0.0%	N/A	0.001%
11/13/2024	Loomis Sayles & Co. L P	150,337	$17.32M	0.0%	-6.2%	0.148%
11/13/2024	Fisher Asset Management LLC	68,270	$7.87M	0.0%	+7.8%	0.067%
11/13/2024	Daiwa Securities Group Inc.	11,798	$1.36M	0.0%	+34.1%	0.012%
11/12/2024	Alpha DNA Investment Management LLC	3,732	$0.43M	0.2%	N/A	0.004%
11/12/2024	Larson Financial Group LLC	1,401	$0.16M	0.0%	-26.0%	0.001%
11/12/2024	Algert Global LLC	18,366	$2.12M	0.1%	N/A	0.018%
11/12/2024	Cerity Partners LLC	39,024	$4.50M	0.0%	+42.4%	0.039%
11/12/2024	Eagle Asset Management Inc.	621,363	$78.13M	0.4%	-8.6%	0.614%
11/12/2024	HealthInvest Partners AB	60,607	$6.98M	3.3%	+156.5%	0.060%
11/12/2024	Charles Schwab Investment Management Inc.	747,291	$86.10M	0.0%	-0.7%	0.738%
11/12/2024	Massachusetts Financial Services Co. MA	163,054	$18.79M	0.0%	+4.5%	0.161%
11/9/2024	Landscape Capital Management L.L.C.	8,684	$1M	0.1%	N/A	0.009%
11/9/2024	Primecap Management Co. CA	404,000	$46.55M	0.0%	-1.3%	0.399%
11/9/2024	Intech Investment Management LLC	102,595	$11.82M	0.1%	+49.3%	0.101%
11/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	819,968	$94.48M	0.2%	+4.7%	0.810%
11/8/2024	Grandfield & Dodd LLC	15,821	$1.82M	0.1%	+1.8%	0.016%
11/8/2024	First Horizon Advisors Inc.	1,007	$0.12M	0.0%	+21.2%	0.001%
11/8/2024	Advisors Asset Management Inc.	38,576	$4.45M	0.1%	+13.4%	0.038%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	17,186	$1.98M	0.0%	+670.7%	0.017%
11/8/2024	Jennison Associates LLC	334,800	$38.58M	0.0%	-32.9%	0.331%
11/8/2024	Commerce Bank	4,199	$0.48M	0.0%	+2.6%	0.004%
11/8/2024	Segall Bryant & Hamill LLC	36,472	$4.20M	0.1%	-1.4%	0.036%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	4,799	$0.55M	0.0%	N/A	0.005%
11/7/2024	Quest Partners LLC	3,495	$0.40M	0.0%	+674.9%	0.003%
11/7/2024	Swiss National Bank	298,700	$34.42M	0.0%	+1.4%	0.295%
11/7/2024	Thrivent Financial for Lutherans	25,802	$2.97M	0.0%	-44.6%	0.025%
11/7/2024	AM Squared Ltd	900	$0.10M	0.2%	N/A	0.001%
11/6/2024	Mutual of America Capital Management LLC	54,573	$6.29M	0.1%	-5.3%	0.054%
11/6/2024	Natixis Advisors LLC	29,327	$3.38M	0.0%	-16.8%	0.029%
11/6/2024	Archer Investment Corp	740	$85K	0.0%	+37.0%	0.001%
11/6/2024	Empowered Funds LLC	62,052	$7.15M	0.1%	+681.7%	0.061%
11/6/2024	Sheaff Brock Investment Advisors LLC	2,238	$0.26M	0.0%	+13.6%	0.002%

Data available starting January 2016

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $135.42

$134.12

$137.01

50 Day Range

MA: $123.99

$115.08

$136.69

52 Week Range

Now: $135.42

$110.95

$157.98

Volume

2,265,589 shs

Average Volume

884,102 shs

Market Capitalization

$13.71 billion

P/E Ratio

36.31

Dividend Yield

N/A

Beta

0.34

Who are the company insiders with the largest holdings of Neurocrine Biosciences?: Neurocrine Biosciences' top insider shareholders include:
Neurocrine Biosciences Inc (Major Shareholder)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
David W Boyer (Insider)
Shalini Sharp (Director)
George J Morrow (Director)
Leslie V Norwalk (Director)
Learn More about top insider investors at Neurocrine Biosciences.
Who are the major institutional investors of Neurocrine Biosciences?: Neurocrine Biosciences' top institutional investors include:
State Street Corp — 5.08%
Bellevue Group AG — 1.84%
Geode Capital Management LLC — 1.84%
Braidwell LP — 0.91%
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC — 0.88%
BNP PARIBAS ASSET MANAGEMENT Holding S.A. — 0.81%
Learn More about top institutional investors of Neurocrine Biosciences stock.
Which institutional investors are selling Neurocrine Biosciences stock?: During the previous quarter, NBIX stock was sold by these institutional investors:
Assenagon Asset Management S.A.
Jacobs Levy Equity Management Inc.
Wellington Management Group LLP
Janus Henderson Group PLC
Jennison Associates LLC
Franklin Resources Inc.
Principal Financial Group Inc.
Principal Financial Group Inc.
During the previous year, company insiders that have sold Neurocrine Biosciences company stock include:
Neurocrine Biosciences Inc (Major Shareholder)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
David W Boyer (Insider)
Shalini Sharp (Director)
George J Morrow (Director)
Learn More investors selling Neurocrine Biosciences stock.
Which institutional investors are buying Neurocrine Biosciences stock?: Within the previous quarter, NBIX stock was bought by institutional investors including:
State Street Corp
Los Angeles Capital Management LLC
Braidwell LP
BNP Paribas Financial Markets
Caisse DE Depot ET Placement DU Quebec
Victory Capital Management Inc.
Citigroup Inc.
Empowered Funds LLC